Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transfusion Clear all
Active, not recruiting Phase 3 Interventional

The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial

NCT02261415
View directory record Official record
Conditions
Cancer, Tumour, Surgery
Interventions
Tranexamic acid (TXA), Normal saline
Drug
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
1,386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 22, 2026, 2:57 PM EDT
Terminated Phase 2 Interventional

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

NCT03381833
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
LJPC-401
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
14 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

A Study for Leukemia Patients With Life-Threatening Infections

NCT00968838
View directory record Official record
Conditions
Leukemia
Interventions
White Blood Cell Transfusion
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

Hydroxyurea and Transfusion

NCT03644953
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hydroxyurea
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 24 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

Cold Stored Platelet in Hemorrhagic Shock

NCT04667468
View directory record Official record
Conditions
Trauma, Hemorrhage
Interventions
Cold Stored Platelets (CSP), Standard Care
Biological
Lead sponsor
Jason Sperry
Other
Eligibility
15 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 22, 2026, 2:57 PM EDT
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
15
States / cities
Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

NCT00067080
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
ICL670, deferoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
34
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 22, 2026, 2:57 PM EDT
Not listed Phase 1 Interventional

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

NCT03385486
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma
Interventions
TBX-3400
Biological
Lead sponsor
Taiga Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Not applicable Interventional Results available

Removing Transfusion Dependence as a Barrier to Hospice Enrollment

NCT05063591
View directory record Official record
Conditions
Hematologic Malignancy, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Lymphoma, Leukemia, Myeloma
Interventions
Transfusion support
Other
Lead sponsor
Adam Olszewski
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbiome of Donor Iron Deficient Study

NCT02990988
View directory record Official record
Conditions
Iron Deficiency
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

NCT00098280
View directory record Official record
Conditions
Hemoglobinuria, Paroxysmal
Interventions
Eculizumab
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 2:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Changes in Pituitary Iron and Volume With Deferasirox

NCT01376622
View directory record Official record
Conditions
Iron Overload
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
2 Years to 25 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

NCT01178281
View directory record Official record
Conditions
Primary Myelofibrosis, MPN-associated Myelofibrosis
Interventions
Pomalidomide 0.5 mg, Placebo, Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
17
States / cities
Scottsdale, Arizona • Los Angeles, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 22, 2026, 2:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Performance Evaluation of T-TAS®01 HD Chip

NCT06087198
View directory record Official record
Conditions
Thrombocytopenia
Interventions
T-TAS 01 HD Assay
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
6
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 22, 2026, 2:57 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)

NCT00799773
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Rituximab, Plasma exchange, Corticosteroids
Drug · Procedure
Lead sponsor
Carelon Research
Other
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

NCT01035229
View directory record Official record
Conditions
Carcinoma
Interventions
Everolimus, Everolimus Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 22, 2026, 2:57 PM EDT
Withdrawn No phase listed Observational

Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome

NCT04969367
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Medical Device Usage and Evaluation, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Other · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 22, 2026, 2:57 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

NCT01499888
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus
Procedure · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
16 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 1 Interventional

Cord Blood Plus Vitamin D and Omega 3s in T1D

NCT00873925
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Autologous UCB, Omega 3 FA, Vitamin D
Biological · Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population

NCT03923959
View directory record Official record
Conditions
Hip Fractures
Interventions
Tranexamic Acid Injectable Solution, Placebo
Drug · Other
Lead sponsor
Lancaster General Hospital
Other
Eligibility
65 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

NCT04987489
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Etavopivat tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Cerritos, California • Los Angeles, California • Oakland, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

Leucovorin for the Treatment of 5 q Minus Syndrome

NCT00004997
View directory record Official record
Conditions
5q Minus Syndrome, Myelodysplastic Syndrome
Interventions
Leucovorin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

NCT05711524
View directory record Official record
Conditions
Hypofibrinogenemia, Bleeding
Interventions
Traditional Cryoprecipitate, Pathogen-Reduced Cryoprecipitate
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 22, 2026, 2:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroimaging of Donor Iron Deficient Study

NCT02990559
View directory record Official record
Conditions
Iron Deficiency
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 22, 2026, 2:57 PM EDT